Home Blog of Signal Transduction Proteases HIV Protease Understanding the impact of halogen functional group (Br, Cl, F, OH) in amprenavir ligand of the HIV protease

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

Understanding the impact of halogen functional group (Br, Cl, F, OH) in amprenavir ligand of the HIV protease

We focused our attention towards the most dreadful disease that threatens the mankind of 20th century - Acquired immunodeficiency syndrome (AIDS), caused through the human immunodeficiency virus (HIV) and a sexually transmitted infection (STI). In this study, our foremost interest was to identify the potency and stability of HIV ligand- Amprenavir (APV) and its modelled functional group (Br, Cl, F, CF3, CH3, NH2) ligands through halogen and hydrogen bond contact, which will have a clear portrait on the structure activity of protein ligand interactions. This will assist chemist in synthesizing novel APV ligands, which are expected to inhibit the activity of HIV-1 protease enzyme. The binding strength of Amprenavir ligand with interacting hinge region amino acid side chains: Isoleucine (ILE 147, 150, 184), Valine (VAL 82), Alanine (ALA 28), Aspartic acid (25, 30, 125, 130) and Glycine (GLY 127, 149) were understood through interaction energy calculations at HF, B3LYP, M052X, MP2 level of theories for different basis set (6-311 G**, LANL2DZ). The present work will reveal an understandable picture about the halogen and hydrogen bond interaction that grip the contact of ligand and amino acids in the hinge region. Overall the Halogen atom (Br, Cl, F) functional groups improved the binding strength of APV in HIV protease; which provide a new novel path for the functional group preference on the ligand that enclose perfectly with the amino acid in the hinge region.

Comments：

The findings of study are quite interesting and important in the field of HIV/AIDS research. By investigating the potency and stability of Amprenavir (APV) and its modeled functional group ligands, you have helped to better understand the structure-activity relationship of protein-ligand interactions, which is crucial in the development of new HIV inhibitors.

The use of different level of theories and basis sets to calculate the binding strength between the ligand and the hinge region amino acid side chains provides valuable insights into the nature of the halogen and hydrogen bond interactions that are involved in this process. The conclusion that halogen atom functional groups (Br, Cl, F) improved the binding strength of APV in the HIV protease is particularly significant and may pave the way for the development of novel APV ligands with improved inhibitory activity against the virus.

Overall, study provides valuable contributions to the field of HIV/AIDS research and highlights the importance of understanding protein-ligand interactions in the development of new antiviral drugs.

Related Products

Cat.No. Product Name Information
S1639 Amprenavir (VX-478) Amprenavir (VX-478, 141W94, KVX-478) is a potent PXR-selective agonist, and an HIV protease inhibitor, used to treat HIV.

Related Targets

HIV Protease